Peliglitazar racemate (BMS 426707-01 racemate)
98%
- Product Code: 64803
CAS:
331744-72-0
| Molecular Weight: | 530.57 g./mol | Molecular Formula: | C₃₀H₃₀N₂O₇ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, airtight, dry |
Product Description:
Peliglitazar racemate is primarily investigated for its potential therapeutic applications in metabolic disorders, particularly type 2 diabetes and dyslipidemia. It functions as a dual agonist of peroxisome proliferator-activated receptors (PPARs), specifically PPAR-alpha and PPAR-gamma, which play key roles in regulating glucose and lipid metabolism. By activating these receptors, it helps improve insulin sensitivity, reduce blood glucose levels, and normalize lipid profiles, making it a promising candidate for managing metabolic syndrome. Its development aims to address the limitations of existing therapies by offering a more comprehensive approach to controlling both hyperglycemia and dyslipidemia simultaneously. However, its clinical use is still under research, with studies focusing on efficacy, safety, and potential side effects.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | ฿936,070.00 |
+
-
|
Peliglitazar racemate (BMS 426707-01 racemate)
Peliglitazar racemate is primarily investigated for its potential therapeutic applications in metabolic disorders, particularly type 2 diabetes and dyslipidemia. It functions as a dual agonist of peroxisome proliferator-activated receptors (PPARs), specifically PPAR-alpha and PPAR-gamma, which play key roles in regulating glucose and lipid metabolism. By activating these receptors, it helps improve insulin sensitivity, reduce blood glucose levels, and normalize lipid profiles, making it a promising candidate for managing metabolic syndrome. Its development aims to address the limitations of existing therapies by offering a more comprehensive approach to controlling both hyperglycemia and dyslipidemia simultaneously. However, its clinical use is still under research, with studies focusing on efficacy, safety, and potential side effects.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :